Drug intelligence / Profile preview

MAF

Development stage: Unknown
Lead developer: Saisei Pharma
Administration: Oral

Overview

MAF (Macrophage Activating Factor) capsules are a dietary supplement intended to modulate immune function, particularly through stimulating or activating macrophages, a type of immune cell. In available studies, such as trials by Saisei Pharma, MAF capsules have been investigated for supportive care in infections including COVID-19, but are not approved pharmaceutical drugs. They are described as dietary supplements and are not classified as pharmaceuticals.

Other names: Saisei MAFMAF capsules

Beyond the preview

Go deeper on MAF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAF.

Explore the full profile